drugset / Trial / NCT02144792
Development and Clinical Application of [11C]Verapamil-PET
Non-randomizedSingle-groupOpen-labelDiagnostic
Summary
The major hypothesis explaining drug resistance is overexpression of p-glycoprotein at the target lesion. Based on several studies, p-glycoprotein (P-gp) has an important role in neurologic diseases, especially in drug resistant epilepsy. But there is no surrogate marker that can quantify the expression of P-gp because of the difficulty in measuring substances in the neurologic system and the lack of clinical trials. Here, the investigators use a novel non-invasive \[11C\] -verapamil Brain PET and SPAM analytic method as a surrogate marker for quantifying the expression of p-glycoprotein.
Timeline
- Start
- 2013-05
- Primary completion
- 2014-05
- Completion
- 2014-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Cyclosporin A | Unknown | 2.5 mg/kg | Intravenous |